

Freedom of Information request 015763

25/6/21

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma:

- Avelumab + Axitinib - 0
- Axinitib - 0
- Cabozantinib - 0
- Everolimus – 3
- Lenvantinib + Everolimus - 0
- Nivolumab - 4
- Nivolumab + Ipilimumab - 0
- Pazopanib - 4
- Pembrolizumab + Axitinib - 0
- Sunitinib - 8
- Temsirolimus - 0
- Tivozanib - 2
- Other

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage):

- Cobimetinib - 0
- Dabrafenib - 0
- Dabrafenib + Trametinib - 0
- Encorafenib + Binimetinib - 0
- Ipilimumab- 0
- Ipilimumab + Nivolumab - 0
- Nivolumab – 4 (can't differentiate between above Nivolumab)
- Pembrolizumab - 8
- Trametinib - 0
- Vemurafenib – 0
- Vemurafenib + Cobimetinib – 0
- Other active systemic anti-cancer therapy
- Palliative care only

3. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY: - Unable to provide this information, the database only picks up melanoma unable to filter by metastatic melanoma

- Cobimetinib
- Dabrafenib
- Dabrafenib + Trametinib
- Encorafenib + Binimetinib
- Ipilimumab
- Ipilimumab + Nivolumab
- Nivolumab
- Pembrolizumab
- Trametinib
- Vemurafenib
- Vemurafenib + Cobimetinib
- Other active systemic anti-cancer therapy
- Palliative care only